046210.KQ Panagene Inc

Healthcare Biotechnology KOSDAQ
1,784 KRW
Close of Oct 30, 2026
980.00 2,940
Market cap
KRW 57.3B
P/E
-
P/B
0.78x
ROE
1.3%
Dividend yield
-
Fundamental score
1.3/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 046210.KQ undervalued?

Graham number

The Graham number of Panagene Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Panagene Inc fundamental analysis

6 of 22 checks passed

ROE 0/2

Low return on equity (1.3%), below 10%.

ROA 1/1

Return on assets (1.2%) is above the industry median (-10.1%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share did not grow over the past 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 0/1

Last year's EPS growth (-50.3%) is below the industry median (4.8%).

Revenue Growth 1/2

Revenue grew 2.0% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 2/2

Low debt to equity (1.5%), 40% or less.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Debt Coverage 0/1

Operating cash flow does not cover 20% of total debt.

Interest Coverage 0/1

EBIT is 3.0x against interest expense, below 5x.

PE vs Market 0/1

PE is negative or not available.

PE vs Industry 0/1

PE is negative or not available.

PBV 1/1

Price to book (0.8x) is below the industry median (2.4x).

Graham Number 0/1

Graham number needs positive earnings and book value.

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Panagene Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Panagene Inc

Panagene Inc. develops products in the field of molecular diagnostics in South Korea. Its products include Liquid biopsy products for lung and colon cancers; tissue biopsy products for lung, thyroid, pancreatic, and colon cancers, as well as glioblastoma, myeloproliferative neoplasm, chronic myelogenous leukemia, central nervous system, myelofibrosis, and polycythemia vera diseases. The company also offers products for cervical cancer, sexually transmitted, and extreme drug …

Full company profile